Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
12.53
+0.20 (1.62%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Y-mAbs Therapeutics Revenue
Y-mAbs Therapeutics had revenue of $19.93M in the quarter ending March 31, 2024, a decrease of -1.58%. This brings the company's revenue in the last twelve months to $84.50M, up 12.62% year-over-year. In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth.
Revenue (ttm)
$84.50M
Revenue Growth
+12.62%
P/S Ratio
6.51
Revenue / Employee
$844,990
Employees
100
Market Cap
549.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cross Country Healthcare | 1.78B |
Sharecare | 419.82M |
Pacific Biosciences of California | 200.43M |
Treace Medical Concepts | 196.03M |
OmniAb | 21.05M |
Jin Medical International | 19.82M |
PureTech Health | 3.33M |
Fulcrum Therapeutics | 2.51M |
YMAB News
- 4 days ago - Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB - GlobeNewsWire
- 25 days ago - Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm - Accesswire
- 7 weeks ago - Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting - GlobeNewsWire
- 7 weeks ago - Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer - GlobeNewsWire
- 7 weeks ago - Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting - GlobeNewsWire
- 7 weeks ago - Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - GlobeNewsWire